Conni Ciavarella
@conniciavarella.bsky.social
Research fellow in mathematical modelling of infectious diseases, Montpellier University
We quantified the community-level impact of routinely treating symptomatic P. vivax cases with PQ or TQ using an existing agent-based model.
- All regimens can achieve a similar impact
- Drug adherence and eligibility criteria hamper impact
- Impact decreases with increasing transmission intensity
- All regimens can achieve a similar impact
- Drug adherence and eligibility criteria hamper impact
- Impact decreases with increasing transmission intensity
January 27, 2025 at 10:06 AM
We quantified the community-level impact of routinely treating symptomatic P. vivax cases with PQ or TQ using an existing agent-based model.
- All regimens can achieve a similar impact
- Drug adherence and eligibility criteria hamper impact
- Impact decreases with increasing transmission intensity
- All regimens can achieve a similar impact
- Drug adherence and eligibility criteria hamper impact
- Impact decreases with increasing transmission intensity
We estimated the patient-level efficacy of PQ and TQ by calibrating a novel mathematical model to clinical trial data.
- Effective treatment can eliminate almost all P. vivax hypnozoites
- PQ and TQ regimens have differing efficacies
- Effective treatment can eliminate almost all P. vivax hypnozoites
- PQ and TQ regimens have differing efficacies
January 27, 2025 at 10:06 AM
We estimated the patient-level efficacy of PQ and TQ by calibrating a novel mathematical model to clinical trial data.
- Effective treatment can eliminate almost all P. vivax hypnozoites
- PQ and TQ regimens have differing efficacies
- Effective treatment can eliminate almost all P. vivax hypnozoites
- PQ and TQ regimens have differing efficacies